While the market volatility remains high and the Australian share market went steady and are back above 5600 levels. After a rally in the last two days post the Christmas holidays, it is recommended to be safe in an uncertain and an oscillating stock market environment. Three stocks from the stable healthcare sector which are under investor discussions are the following.
STARPHARMA HOLDINGS LIMITED (ASX: SPL) – The company received advice from the US FDA that before approving VivaGel® BV and the prevention of recurrent BV it will require confirmatory clinical data. The company wishes to meet with the FDA as soon as possible to discuss the additional data required for approval. The success is possible through the strategic utilization of their proprietary dendrimer platform technology. The company is entitled to receive a share of sales revenue from the product as well as up to US$24.7 million in milestone payments. As of September 30, 2018, the cash is at A$ 49.5 million. The stock is trading down by -2.538% at around $0.960 under the health care sector, and the market cap at current price is $366.05 million. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
RESONANCE HEALTH LIMITED (ASX: RHT) – After the recent increase in the volumes of securities traded and the price of the company’s securities, there has not been any update related to the same. Making it the only regulatory approved AI tool for use in liver iron quantification, the company’s AI solution for the justification of liver iron concentration (LIC), achieves TGA and CE Mark clearance. As of September 30, 2018, the cash is at A$ 2.03 million. The company has a very high P/E of 115.00 and EPS of 0.001 AUD. The stock is trading down by -5.797% at around $0.065 under the health care sector, and the market cap at current price is $27.77 million.
MESOBLAST LIMITED (ASX: MSB) – With the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry the company will enter 2019. Two commercial products have already been approved and marketed by the company’ in Japan and have recently entered into a strategic cardiovascular partnership for China with Tasly Pharmaceutical Group. Mesoblast’s milestone payments and royalty income from licensees continues to grow; the Company has enough cash to achieve key commercial milestones. As of September 30, 2018, the cash is at A$ 95.1 million. The stock is trading up by 15.385% at around $1.200 under the health care sector, and the market cap at current price is $517.26 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.